Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc. as indicated in metadata) on March 2, 2011. The filing discloses corporate governance and compensation actions taken by the Board of Directors on that date regarding Named Executive Officers (NEOs).
Key Financial Metrics and Compensation
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments:
- Restricted Stock Units (RSUs): Granted to five NEOs under the 2011 Equity Incentive Plan. Total units granted: 381,966.
- Base Salaries: 2011 base salaries approved for five NEOs, effective retroactively to January 1, 2011.
- Bonus Payment: A one-time bonus of $21,750 approved for the Chief Financial Officer for 2010 performance.
Material Changes and Compensation Details
The following specific compensation changes were approved:
| Executive Officer | RSUs Granted | 2011 Base Salary | Notes |
|---|---|---|---|
| Richard A. King (CEO) | 123,457 | $411,600 | RSUs vest 25% annually over 3 years. |
| Thomas A. Schreck (Former CEO) | 59,145 | N/A | Resigned as CEO April 30, 2010; remains on Board. |
| Pamela P. Palmer (CMO) | 67,594 | $385,000 | RSUs vest 25% annually over 3 years. |
| Lawrence G. Hamel (CDO) | 16,899 | $283,000 | RSUs vest 25% annually over 3 years. |
| Badri Dasu (CEO) | 14,871 | $270,500 | RSUs vest 25% annually over 3 years. |
| James H. Welch (CFO) | N/A | $290,000 | Received $21,750 bonus for 2010 (pro-rated). |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. The primary contingency noted is that RSU vesting is contingent upon the recipient's "Continuous Service" and will cease upon termination of employment.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2011 Equity Incentive Plan to assess dilution impact from the 381,966 RSUs granted.
- Confirm the vesting schedule details (25% annually over 36 months) against the specific RSU Agreement filed as Exhibit 99.5.
- Note that Thomas A. Schreck, while no longer CEO, received a significant RSU grant (59,145 units) as a board member.
- Review the pro-rated bonus calculation for the CFO to ensure alignment with the 30% target bonus clause in his employment agreement.